Long-term Safety and Tolerability of BHV-7000

Brief summary (registry, in English)

A study to determine if BHV- 7000 is safe and tolerable in adults with refractory focal onset epilepsy

What you commit to

• Study type: Interventional · Phase 2
• Planned participants: 660
• From 30 Jul 2024 to the primary completion date, 31 Dec 2026
• 280 sites in 27 countries
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (280)

Sites in registry order. Pick your city on the disease page to sort them by distance.